更精确界定儿童ALL移植前后风险:移植前与移植后MRD、连续阳性及风险模型
双变量分析显示移植前任何水平MRD的预测性均低于移植后低水平MRD;移植前MRD阳性者须在移植后1-2个月降至低/阴性、3-6个月转阴才能治疗成功。基于欧洲、北美和澳大利亚MRD队列建立的风险评分在验证队列中2年累积复发率分别为13%、26%、47%(P < .001)。
要点
- 移植后低水平MRD比移植前任何水平MRD预测性更强
- 移植前MRD阳性者须在移植后1-2个月降至低/阴性、3-6个月转阴
- 移植后可检测MRD患者中,发生急性GVHD与结局改善相关
核心结论
- 移植后MRD比移植前MRD更能预测儿童ALL异基因移植后的复发。
- 移植前MRD阳性患者须在移植后1-2个月降至MRD低/阴性、3-6个月转阴方为治疗成功。
- 基于移植前MRD等负性特征的风险评分可区分2年复发风险不同的三组患者。
研究设计与样本
- 研究比较移植前与移植后MRD的预后价值,分析移植后与MRD阳性患者结局改善相关的临床因素,并建立和验证复发预后模型。
- 风险评分在来自欧洲、北美和澳大利亚的MRD队列中推导,并在第二个更 contemporaneous 队列中验证。
主要发现
- 单变量分析中移植前高和极高MRD是显著预测因素,但双变量分析中移植前任何水平MRD的预测性均低于移植后低水平MRD。
- 移植后可检测MRD患者中,发生急性GVHD与结局改善相关。
- 推导队列中好、中、差风险组2年累积复发率分别为21%、38%、47%。
- 验证队列中好、中、差风险组2年累积复发率分别为13%、26%、47%(P < .001)。
关键数值与推荐
- 风险评分采用负性预测特征:晚期疾病状态、非全身照射方案、MRD(高、极高)定义好、中、差风险组。
- 推导队列2年累积复发率:好21%、中38%、差47%。
- 验证队列2年累积复发率:好13%、中26%、差47%(P < .001)。
临床怎么用
- 儿童ALL异基因移植后应监测MRD,移植后MRD状态比移植前MRD更具预后价值。
- 移植前MRD阳性患者应争取在移植后1-2个月降至MRD低/阴性、3-6个月转阴。
- 可利用基于移植前MRD等特征的风险评分对患者进行风险分层,指导复发监测与干预。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Detection of minimal residual disease (MRD) pre- and post-hematopoietic cell transplantation (HCT) for pediatric acute lymphoblastic leukemia (ALL) has been associated with relapse and poor survival. Published studies have had insufficient numbers to: (1) compare the prognostic value of pre-HCT and post-HCT MRD; (2) determine clinical factors post-HCT associated with better outcomes in MRD+ patients; and (3) use MRD and other clinical factors to develop and validate a prognostic model for relapse in pediatric patients with ALL who undergo allogeneic HCT. To address these issues, we assembled an international database including sibling (n = 191), unrelated (n = 259), mismatched (n = 56), and cord blood (n = 110) grafts given after myeloablative conditioning. Although high and very high MRD pre-HCT were significant predictors in univariate analysis, with bivariate analysis using MRD pre-HCT and post-HCT, MRD pre-HCT at any level was less predictive than even low-level MRD post-HCT. Patients with MRD pre-HCT must become MRD low/negative at 1 to 2 months and negative within 3 to 6 months after HCT for successful therapy. Factors associated with improved outcome of patients with detectable MRD post-HCT included acute graft-versus-host disease. We derived a risk score with an MRD cohort from Europe, North America, and Australia using negative predictive characteristics (late disease status, non-total body irradiation regimen, and MRD [high, very high]) defining good, intermediate, and poor risk groups with 2-year cumulative incidences of relapse of 21%, 38%, and 47%, respectively. We validated the score in a second, more contemporaneous cohort and noted 2-year cumulative incidences of relapse of 13%, 26%, and 47% (P < .001) for the defined risk groups.
引用
- Bader P, Salzmann-Manrique E, Balduzzi A, et al. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv. 2019. PMID: 31714961. doi:10.1182/bloodadvances.2019000449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。